Irazu Oncology
Irazu Oncology is a biotechnology company founded in 2022, dedicated to developing next-generation cancer immunotherapies using proprietary Outer Membrane Vesicles (OMV) platform. The company's mission is to create accessible, affordable, and effective cancer treatments by harnessing engineered bacterial nanoparticles to deliver cancer antigens, activating robust immune responses. Their lead candidate, IRZ-01, targets multiple solid tumor types and aims to provide immediate treatment options following diagnosis. The company is led by a team with over 100 years of drug development experience and is supported by notable investors and research institutions.
Industries
Nr. of Employees
small (1-50)
Irazu Oncology
Baltimore, Maryland, United States, North America
Products
IRZ-01 (OMV-based cancer vaccine candidate)
A preclinical vaccine candidate using an OMV-derived platform engineered to present tumor-associated antigens (examples cited: MUC1 and CEA) intended for multiple solid tumor indications; reported preclinical efficacy includes complete tumor remissions and protective immune responses against recurrence.
IRZ-03
IRZ-03 is a first-in-class OMV immunotherapy that attacks solid tumors on two fronts in a single off-the-shelf agent — directing the immune system against the tumor antigens CEA and MUC1 while targeting PD-L1 on the immunosuppressive cells that disarm anti-tumor immunity. It is purpose-built for the patients checkpoint inhibitors leave behind: colorectal, non-small cell lung, gastric, pancreatic, and head and neck cancers.
IRZ-01 (OMV-based cancer vaccine candidate)
A preclinical vaccine candidate using an OMV-derived platform engineered to present tumor-associated antigens (examples cited: MUC1 and CEA) intended for multiple solid tumor indications; reported preclinical efficacy includes complete tumor remissions and protective immune responses against recurrence.
IRZ-03
IRZ-03 is a first-in-class OMV immunotherapy that attacks solid tumors on two fronts in a single off-the-shelf agent — directing the immune system against the tumor antigens CEA and MUC1 while targeting PD-L1 on the immunosuppressive cells that disarm anti-tumor immunity. It is purpose-built for the patients checkpoint inhibitors leave behind: colorectal, non-small cell lung, gastric, pancreatic, and head and neck cancers.
Expertise Areas
- Cancer vaccine development
- Preclinical oncology and tumor immunology
- Antigen targeting and selection
- Bioprocess scale-up for microbial-derived therapeutics
Key Technologies
- Bacterial outer membrane vesicles (OMVs)
- Engineered bacterial-derived nanoparticles
- Tumor-associated antigen targeting (e.g., MUC1, CEA)
- Nanoparticle size engineering for lymphatic delivery
News & Updates
Irazú Oncology announced the closing of bridge financing and key organizational developments, including the appointment of a Chief Medical Officer and expansion of its research facilities.
Highlighting Irazu Oncology as one of the innovative startups shaping the future of entrepreneurship in Baltimore.
Coverage of biotech successes in Baltimore, including Irazu Oncology.
Funding news about Irazu Oncology securing seed investment to develop its cancer vaccine platform.
Investment news about the backing from Maryland research funds and university.
Irazú Oncology announced the closing of bridge financing and key organizational developments, including the appointment of a Chief Medical Officer and expansion of its research facilities.
Highlighting Irazu Oncology as one of the innovative startups shaping the future of entrepreneurship in Baltimore.
Coverage of biotech successes in Baltimore, including Irazu Oncology.
Funding news about Irazu Oncology securing seed investment to develop its cancer vaccine platform.
Investment news about the backing from Maryland research funds and university.